Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: 180 Life Sciences Corp.

Flora Growth Corp. (NASDAQ: FLGC) Year-end Report Shows Significant Revenue and Profit Growth, with Expectations for Further Rapid Growth in 2022

Cannabis cultivator and distributor Flora Growth has announced its annual financial and operating results, showing “significantly higher” revenues and profit gain for 2021 over the previous yearFlora maintains an outlook for 2022 of an additional 288 to 400 percent revenue … Continue reading

Posted in 180 Life Sciences Corp., Flora Growth Corp. FLGC | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into securities purchase agreements with certain institutional investors to raise … Continue reading

Posted in 180 Life Sciences Corp., MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at … Continue reading

Posted in 180 Life Sciences Corp., MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to … Continue reading

Posted in 180 Life Sciences Corp., MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Completion of Strategic Merger

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. … Continue reading

Posted in 180 Life Sciences Corp., MissionIRNewsBreaks | Leave a comment

SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space

Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnesses A planned merger with 180 Life Sciences advanced under a special purpose acquisition corporation (SPAC) … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions

180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM, MissionIRNewsBreaks | Leave a comment

180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents

The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China 180 Life Sciences is in the final stages of its merger process with KBL Merger Corp. … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions

180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions. Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021 … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Continues to Broaden Global IP Portfolio, Expand Internal Pipeline

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously entered a definitive agreement to acquire 180 Life Sciences, a clinical-stage biotechnology company, on Tuesday … Continue reading

Posted in 180 Life Sciences Corp., MissionIRNewsBreaks | Leave a comment